Patrick Lucy

Patrick Lucy is an accomplished biotechnology executive with over 34 years of industry experience. Patrick is currently the President and Chief Executive Officer of Wheeler Bio, Inc., an agile contract development and manufacturing organization focused on the production of biological based therapeutics. As a seasoned senior executive, he has overseen numerous company milestones and driven significant growth. Patrick most recently served as President and CEO of RoslinCT US (formerly Lykan Bioscience), a cell therapy contract manufacturer based in Hopkinton, Massachusetts, and Edinburgh, Scotland. Under his leadership, he led the successful launch of the Lykan business and, just 19 months later, orchestrated its sale to GHO Capital, providing a successful exit for the original private equity investors. Following this acquisition, GHO integrated Lykan and RoslinCT under the RoslinCT name, further solidifying their market presence. Prior to Lykan Bioscience, Patrick was a founder and served in the roles of Senior Vice President and Chief Business Officer, and Interim Chief Executive Officer at Pfenex, Inc., a publicly traded biotechnology company (NYSE: PFNX) that started as a venture backed spin-out from The Dow Chemical Company in 2009 and was later acquired by Ligand Pharmaceuticals in October 2020 for up to $512 million. Earlier in his career, he held positions at Repligen Corporation, Celltech Biologics, Lonza Biologics, and Collaborative BioAlliance.